Roche Holding AG (XSWX:RO) Debt-to-Asset : 0.33 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:RO Roche Holding AG XSWX:RO
76 GF Score
Price CHF339.60
GF Value CHF268.94
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Debt-to-Asset?

Roche Holding AG XSWX:RO +0.83% 76 Debt-to-Asset is 0.33 as of Dec. 2025. GuruFocus rates XSWX:RO with a GF Score™ of 76/100 and a GF Value™ of CHF268.94 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Roche Holding AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was CHF4,517 Mil. Roche Holding AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was CHF28,674 Mil. Roche Holding AG's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2025 was CHF100,703 Mil. Roche Holding AG's debt to asset for the quarter that ended in Dec. 2025 was 0.33.

Roche Holding AG  (XSWX:RO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Roche Holding AG Debt-to-Asset Related Terms

Roche Holding AG Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Roche Holding AG's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roche Holding AG Debt-to-Asset Chart

Roche Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.30 0.34 0.36 0.33

Roche Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.36 0.36 0.35 0.33

XSWX:RO vs LLY, JNJ, ABBV: Debt-to-Asset Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roche Holding AG Debt-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's Debt-to-Asset falls into.


XSWX:RO
76GF Score
Roche Holding AG XSWX:RO
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roche Holding AG Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Roche Holding AG's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(4517 + 28674) / 100703
=0.33

Roche Holding AG's Debt-to-Asset for the quarter that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(4517 + 28674) / 100703
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.33 mean?
Roche Holding AG (XSWX:RO) has a Debt-to-Asset of 0.33 as of Dec. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Roche Holding AG and its competitors.
Is Roche Holding AG's Debt-to-Asset too high?
Roche Holding AG's current Debt-to-Asset is 0.33. Overall, Roche Holding AG has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Debt-to-Asset compare to LLY and JNJ?
Roche Holding AG's Debt-to-Asset of 0.33 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Roche Holding AG and its competitors. Roche Holding AG's current Debt-to-Asset is 0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF268.94, compared to a current price of CHF339.60 — trading 26.3% above its estimated fair value. The current Debt-to-Asset is 0.33. Roche Holding AG's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current Debt-to-Asset is 0.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (XSWX:RO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of CHF339.60 is trading 26.3% above its estimated GF Value™ of CHF268.94. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for XSWX:RO:

  • Debt-to-Asset: 0.33
  • GF Value™: CHF268.94 vs. price of CHF339.60 (26.3% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
76GF Score

Get the complete analysis for XSWX:RO

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF339.60
Price
CHF268.94
GF Value